

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  26D0046398	<b>(X3) Date Survey Completed</b>  12/08/2020
<b>Name of Provider or Supplier</b>  Salem Memorial District Hospital	<b>Street Address, City, State</b>  35629 Hwy 72, Salem, MO	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D2016</b>	<p><b>SUCCESSFUL PARTICIPATION</b> CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: Based on review of 2020 immunohematology compatibility testing proficiency testing (PT) results reported to the CLIA database by the PT provider and phone interview with the technical consultant, the laboratory failed to successfully participate in PT. See tag D2181 unsatisfactory performance in two out of three consecutive testing events for the analyte; compatibility testing.</p>
<b>D2181</b>	<p><b>COMPATIBILITY TESTING</b> CFR(s): 493.863(e)</p>

Failure to achieve an overall testing event score of satisfactory for two consecutive testing events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:

Based on review of 2020 immunohematology proficiency testing (PT) results reported to the CLIA database by the PT provider and phone interview with the technical supervisor (TS), the laboratory failed to achieve satisfactory performance for compatibility testing in two out of three testing events. Findings: 1. Review of the immunohematology PT results for the first event of 2020 revealed the laboratory obtained an unsatisfactory score of 80 percent for compatibility testing. 2. Review of the immunohematology PT results for the third event of 2020 revealed the laboratory obtained an unsatisfactory score of 80 percent for compatibility testing. 3. Interview with the TS on December 07, 2020 at 8:28 AM confirmed the laboratory failed to achieve satisfactory performance for compatibility testing in two out of three consecutive events in 2020.